AstraZeneca held talks with Bristol Myers Squibb on $400 billion megadeal, source says
By Sabrina Valle and Michael Erman Aug 2 (Reuters) - AstraZeneca Plc and Bristol Myers Squibb held preliminary discussions about a possible combination that would create one of the world's biggest pharmaceutical companies with a combined value of nearly $400 billion, according to a person familiar